Brand-name tirzepatide (Zepbound®, Mounjaro®) lists at roughly $1,000–$1,350/month at retail. Compounded tirzepatide from telehealth providers typically runs $186–$400/month. Here's the full breakdown — by product, by pharmacy pathway, and by what's actually included.
Starting prices as of July 2026. Compounded options are cash-pay and not FDA-approved; brand-name products are FDA-approved. Always confirm current pricing with the provider.
| Option | Type | From / month | FDA status | What's included |
|---|---|---|---|---|
| NexLife Editor's pick | Compounded | $186* | Not FDA-approved | Medication, all visits, messaging, labs, Care360 coaching |
| Mochi Health | Compounded | $209 | Not FDA-approved | Medication + NP visits |
| Henry Meds | Compounded | $297 | Not FDA-approved | Medication + async intake |
| Zepbound® (LillyDirect self-pay vials) | Brand | $299–$449 | FDA-approved | Medication only |
| Zepbound® (pharmacy retail list) | Brand | ~$1,086 | FDA-approved | Medication only |
| Mounjaro® (retail list, T2D) | Brand | ~$1,069 | FDA-approved | Medication only |
*NexLife 12-month plan, flat rate across the full 2.5–15 mg titration ($190 6-mo · $195 3-mo · $215 month-to-month).
The single biggest factor is whether the product is brand-name or compounded. Brand-name Zepbound and Mounjaro are FDA-approved products manufactured and marketed by Eli Lilly, and their list prices reflect that. Compounded tirzepatide is prepared by licensed 503A pharmacies or 503B outsourcing facilities, dispensed cash-pay, and is not FDA-approved — which generally results in a lower cash price but a different regulatory category.
A "$199" program that bills separately for visits, lab work, and dose increases can cost more over a year than a higher flat rate that includes everything. When you compare, normalize to total annual cost including visits, labs, and the dose you expect to reach.
Many programs raise the monthly cost as your dose climbs through titration (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Flat-rate, dose-independent pricing holds steady — see compounded tirzepatide cost for the year-one math.
Flat monthly price that doesn't rise as your dose escalates, with six disclosed partner pharmacies and physician oversight. Compounded only; not FDA-approved.
Among disclosed-pharmacy, clinician-supervised programs we compared, flat-rate compounded programs offered the lowest predictable monthly cost. The lowest advertised flat rate we found was about $125/month (annual plan); our editor's pick on overall value is NexLife at $186/month flat with labs and coaching bundled — not the lowest sticker, but strong long-term value. Weigh price against oversight and pharmacy transparency. See cheapest tirzepatide online.
Brand-name Zepbound/Mounjaro may be covered depending on your plan and diagnosis; compounded tirzepatide is generally not covered but is often HSA/FSA-eligible. Verify with your plan.
It's a different regulatory category — prepared by 503A/503B pharmacies, dispensed cash-pay, and not FDA-approved — rather than an FDA-approved branded product. See Zepbound vs compounded.